Atherosclerosis. Supplements最新文献

{"title":"Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk","authors":"Lale Tokgözoğlu ,&nbsp;Manuela Casula ,&nbsp;Angela Pirillo ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.001","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.001","url":null,"abstract":"<div><p>The 2018 American Heart Association/American College of Cardiology/Multi-Society (AHA/ACC/MS) Guideline on the Management of Blood Cholesterol and the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines for the Management of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk, that were recently released by the United States and Europe, provide new recommendations for the management of blood lipid levels based on the latest evidence. Despite many common points, there are several differences in the recommendations, including the definition of very-high-risk patient category, the recommendations for some categories of patients, such as those with diabetes, familial hypercholesterolemia, chronic kidney disease, and aged patients, and the use of ezetimibe and PCSK9 inhibitors. These differences suggest that multiple approaches can be used to manage lipid abnormalities in the context of cardiovascular risk reduction.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPIGEN in Italy and of other networks for familial hypercholesterolemia","authors":"Marta Gazzotti ,&nbsp;Manuela Casula ,&nbsp;Elena Olmastroni ,&nbsp;Maurizio Averna ,&nbsp;Marcello Arca ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.007","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.007","url":null,"abstract":"<div><p>Familial hypercholesterolemia (FH) is a common genetic disorder of lipid metabolism, still underdiagnosed and undertreated in the general population. Pathology registers could play a crucial role in the creation of a comprehensive and integrated global approach to cover all aspects of this disease. Systematic data collection of patients affected by FH has increased dramatically worldwide in the past few years. Moreover, results from registers already established for the longest time showed their potentialities in the implementation of the knowledge of FH, comparing country-specific approaches and providing real-world data about identification, management and treatment of FH individuals in the clinical practice.</p><p>The potential fields of research through registers are related to the deepening of the genetic basis of disease, the study of genotype-phenotype correlation, the local adaption and implementation of diagnostic algorithms, the comparison of pharmacological approaches and treatment gaps in real-life clinical practice, the evaluation of specific subpopulations, and the identification of factors modifying cardiovascular disease risk. Registers could become also a valid resource for other rare dyslipidaemias, contributing towards the evidence-based enhancement in the worldwide care of uncommon diseases.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives","authors":"Marco Alings ,&nbsp;Olivier Descamps ,&nbsp;Benoit Guillon ,&nbsp;Margret Leosdottir ,&nbsp;Aldo P. Maggioni ,&nbsp;Lluis Recasens ,&nbsp;Walter S. Speidl ,&nbsp;Rosario V. Tripodi ,&nbsp;Ulf Landmesser ,&nbsp;Alberico L. Catapano ,&nbsp;Angela Pirillo","doi":"10.1016/j.atherosclerosissup.2021.01.010","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.010","url":null,"abstract":"<div><p>Post-acute coronary syndrome (ACS) patients are at very high cardiovascular risk. Despite current guidelines strongly recommend to reduce LDL-C levels and initiation of high-intensity statins as early as possible in patients admitted with an ACS, less than half of ACS patients receive a high intensity statin, and a high percentage of has LDL-C well above the goal despite therapy. There are multiple reasons for that, including physician lack of guideline adherence, patient lack of compliance with treatment, and lack of standardized procedures. Furthermore, although the prevalence of familial hypercholesterolemia is higher among patients with ACS, this condition remains poorly estimated. To fill these gaps, some European countries have launched local initiatives for the in-hospital and post-discharge ACS patient lipid management. It appears that ensuring optimal therapy during hospitalization and dedicated follow-up protocols results in a significant improvement of lipid levels in these very high risk patients, which may translate into a reduced risk of recurrent future events.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.","authors":"A. Sionis, A. Catapano, G. D. de Ferrari, D. Dudek, J. Jukema, U. Landmesser, A. Pirillo, F. Schiele, A. Zaman, J. Zamorano","doi":"10.1016/j.atherosclerosis.2020.10.809","DOIUrl":"https://doi.org/10.1016/j.atherosclerosis.2020.10.809","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91185247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title page","authors":"","doi":"10.1016/S1567-5688(21)00014-3","DOIUrl":"https://doi.org/10.1016/S1567-5688(21)00014-3","url":null,"abstract":"","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1567-5688(21)00014-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138391838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project","authors":"Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;Michel Farnier ,&nbsp;J. Wouter Jukema ,&nbsp;Ulrich Laufs ,&nbsp;François Mach ,&nbsp;Luis Masana ,&nbsp;Terje R. Pedersen ,&nbsp;François Schiele ,&nbsp;Gabriel Steg ,&nbsp;Marco Tubaro ,&nbsp;Azfar Zaman ,&nbsp;Pepe Zamorano ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.009","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.009","url":null,"abstract":"<div><h3>Background and aims</h3><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was to evaluate the compliance to ESC/EAS guidelines during the management of ACS patients and the effectiveness of secondary prevention in seven European countries.</p></div><div><h3>Methods</h3><p>By means of an online questionnaire, data on 2775 ACS patients (either acute case or follow-up patients) were collected, including data on lipid profile, medications, follow-up visit planning, screening for familial hypercholesterolemia.</p></div><div><h3>Results</h3><p>Lipid profiles were obtained for 91% of ACS patients in the acute phase, mostly within the first day of hospitalization (73%). During hospitalization, 93% of the patients received a lipid-lowering treatment; at discharge, only 66% of the patients received a high intensity statin therapy. At the first follow-up, most of the patients (77.6%) had LDL-C &gt;70 mg/dL; among them, 41% had no change in their lipid-lowering therapies. Similar data were obtained during the second follow-up visit. The analysis of a subgroup of patients with at least 2 follow-up visits and known LDL-C levels showed that the percentage of patients at goal increased from 9% to 32%, and patients with LDL-C &lt;100 mg/dL raised from 23% to 72%. Among acute cases, 44 were admitted with a diagnosis of familial hypercholesterolemia (FH); only 18% of the remaining patients were screened for FH.</p></div><div><h3>Conclusions</h3><p>Contemporary lipid management of very high CV risk patients is sub-optimal despite available treatments. Greater efforts are warranted to optimize cardiovascular prevention.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘Diet and lifestyle’ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members","authors":"Elke A. Trautwein ,&nbsp;Alberico L. Catapano ,&nbsp;Lale Tokgözoğlu","doi":"10.1016/j.atherosclerosissup.2021.01.003","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.003","url":null,"abstract":"<div><p>To better understand the level of knowledge and interest in ‘diet and lifestyle’ for cholesterol management and CVD prevention, European Atherosclerosis Society (EAS) members were invited to take part in an online survey. In total, 269 EAS members participated of which 64 (24%) were students/postdocs, 102 (38%) researchers involved with CVD-related research and 103 (38%) doctors and clinicians who directly interact with patients. All (99%) of the participants either agreed or strongly agreed that ‘diet and lifestyle’ have a role to play in cholesterol management, with 80% indicating that ‘diet and lifestyle’ is very or extremely important. Of the clinicians, 75% indicated that their patients voluntarily ask for ‘diet and lifestyle’ advice and over 80% said they continuously provide ‘diet and lifestyle advice’ to their patients. Of the surveyed clinicians, 91% feel sufficiently educated and confident to provide expert advice and over 90% recommend medication, diet change, frequent exercise and smoking cessation to their patients. In view of more specific dietary advice, clinicians reportedly recommend a ‘Mediterranean diet’, and advise to avoid high-fat foods, and to increase intake of high-fibre foods. Interestingly, smoking cessation and alcohol avoidance were mentioned less frequently. In view of educational needs, over half of the surveyed EAS members use the internet and ‘guidelines’ to learn about ‘diet and lifestyle’ in relation to cholesterol and CVD risk management. Clinicians tend to use ‘guidelines’ more often, while students/postdocs tend to use the internet significantly more than clinicians and CVD researchers. Regarding unmet needs for educational tools addressing specifically ‘diet and lifestyle’, clinicians feel that patient-oriented leaflets and pocket guidelines would be most beneficial materials to introduce, while students/postdocs would prefer an app. In summary, the role of ‘diet and lifestyle’ as a cornerstone of cholesterol management and CVD risk prevention seems well recognised amongst EAS members surveyed.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy","authors":"Bernhard Föger ,&nbsp;Catriona Jennings ,&nbsp;Angela Pirillo ,&nbsp;Lale Tokgözoğlu ,&nbsp;Matteo Pirro ,&nbsp;Alberico L. Catapano","doi":"10.1016/j.atherosclerosissup.2021.01.005","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.005","url":null,"abstract":"<div><p>The availability of efficient lipid-lowering drugs has substantially reduced the incidence and mortality for cardiovascular disease (CVD). Despite that, CVD still represents a major cause of death and disability; efforts are thus required to prevent this disease, since reducing the established CV risk factors may slow or prevent the onset of cardiovascular events. Current guidelines recommend a healthier lifestyle for all CV risk categories, as it may have a beneficial impact on several risk factors; in individuals with a low-to-moderate hypercholesterolemia, which are not eligible for a pharmacological approach and are not far from the cholesterol target recommended for their risk category, functional foods or nutraceuticals may be considered as supplement to reduce their CV risk status. Of note, counseling and lifestyle intervention in people at moderate CV risk represents a major issue for both preventing a further risk increase and reducing the need for drugs. Studies on general populations have clearly indicated that lifestyle interventions translate into a clinical benefit, with reduction of the incidence of myocardial infarction and the risk of developing type 2 diabetes.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool","authors":"Alessandro Sionis ,&nbsp;Alberico L. Catapano ,&nbsp;Gaetano M. De Ferrari ,&nbsp;Dariusz Dudek ,&nbsp;J. Wouter Jukema ,&nbsp;Ulf Landmesser ,&nbsp;Angela Pirillo ,&nbsp;François Schiele ,&nbsp;Azfar Zaman ,&nbsp;Jose L. Zamorano","doi":"10.1016/j.atherosclerosissup.2021.01.011","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.011","url":null,"abstract":"<div><p>Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. In 2018, the ACS EuroPath Survey, performed in collaboration with 555 European cardiologists, identified a sub-optimal LDL-C management in post-ACS patients.</p><p>Based on these premises, the ACS EuroPath II project led to the development of a self-assessment tool to improve lipid management in these very high risk patients, taking into consideration the new 2019 ESC/EAS guidelines. This tool is built in 3 sections. The first is a questionnaire to assess the lipid management practice from the acute phase up to 12 months of follow-up. The main topics covered in this section relate to 1) acute phase (lipid management of ACS patients during hospitalization; 2) discharge (lipid management at discharge, with focus on follow-up plan); 3) follow-up (lipid management at the time of first and subsequent follow-ups); 4) referral pathway for definitive lipid management care of post-ACS patients; 5) evaluation of the achieved goal at 6 months to 1 year and key implications. The second section is a brief report to position the results against other European Union clinical practice and European guidelines. The last section allows the physician to evaluate and consider the implementation of one or more strategies, successfully developed in leading European centers, in order to optimize their own clinical practice.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25370374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study","authors":"Jacek J. Jóźwiak ,&nbsp;Krzysztof Studziński ,&nbsp;Tomasz Tomasik ,&nbsp;Adam Windak ,&nbsp;Mirosław Mastej ,&nbsp;Alberico L. Catapano ,&nbsp;Kausik K. Ray ,&nbsp;Dimitri P. Mikhailidis ,&nbsp;Peter P. Toth ,&nbsp;George Howard ,&nbsp;Gregory Y.H. Lip ,&nbsp;Maciej Tomaszewski ,&nbsp;Fadi J. Charchar ,&nbsp;Naveed Sattar ,&nbsp;Bryan Williams ,&nbsp;Thomas M. MacDonald ,&nbsp;Dariusz Nowak ,&nbsp;Łukasz Skowron ,&nbsp;Sławomir Kasperczyk ,&nbsp;Maciej Banach","doi":"10.1016/j.atherosclerosissup.2021.01.004","DOIUrl":"10.1016/j.atherosclerosissup.2021.01.004","url":null,"abstract":"<div><h3>Background and aim</h3><p>To estimate the prevalence of cardiovascular (CV) disease and CV risk factors among Polish patients.</p></div><div><h3>Methods</h3><p>A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult patients that sought medical care in primary health care practices.</p></div><div><h3>Results</h3><p>Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60% of the recruited patients had hypertension (HTN), &gt;80% had dyslipidaemia and &lt;15% of patients were diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the waist circumference exceed norm for the European population. Less than half of the patients were current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure and glucose levels but lower low density lipoprotein-cholesterol level.</p></div><div><h3>Conclusions</h3><p>The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more common in men than in women. The most common CV risk factors are excess waist circumference, dyslipidaemia and HTN. Family physicians should conduct activities to prevent, diagnose early and treat CVD in the primary health care population.</p></div>","PeriodicalId":8592,"journal":{"name":"Atherosclerosis. Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.atherosclerosissup.2021.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}